-
Thursday, May 31, 2012 - 12:52pm
Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge?Dear Vivus (NASDAQ: VVUS) investors: You are paying $2.5 billion for a company with zero profits in a market space valued at only $3.5 billion annually. Yes, the FDA advisory committee recommended Qnexa be granted approval in a 20-to-2 vote, but remember that Provenge had a unanimous safety vote...
Read More >>


